---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-019616"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:28:10.975199+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioLife Q2 rev $40.5M (+30% YoY); net loss $72.6M on $69.9M impairment; guides FY22 rev $160-166M

## Summary
- Q2 2022 revenue $40.5M, up 30% YoY; organic growth 44%; biopreservation media revenue up 46%.
- GAAP net loss $72.6M ($1.71 loss per share) vs net income $7.9M ($0.19 EPS) in Q2 2021; includes $69.9M non-cash impairment charge.
- Adjusted EBITDA positive $1.5M in Q2 2022 vs $3.7M in Q2 2021; adjusted gross margin 36% vs 43% prior year.
- Full-year 2022 revenue guidance updated to $160M-$166M (34-39% growth) with positive adjusted EBITDA expected.
- Cash and marketable securities $46.6M as of June 30, 2022; down $12.9M from March 31 due to working capital and capex.

## SEC filing metadata
- accession: 0001437749-22-019616
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000143774922019616/0001437749-22-019616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000143774922019616/bioli20220809_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-019616
- JSON: https://secwatch.observer/filing/0001437749-22-019616.json
- Plain text: https://secwatch.observer/filing/0001437749-22-019616.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.